What should the initial antibiotherapy for acute community acquired pneumonia be? How should it be reassessed in case of failure, given the evolution of responsible pathogens and the resistance of pneumococci? Should combined treatment be used?-Reference-Cited by-同舟云学术

What should the initial antibiotherapy for acute community acquired pneumonia be? How should it be reassessed in case of failure, given the evolution of responsible pathogens and the resistance of pneumococci? Should combined treatment be used?

Published:2001-01 Issue:5 Volume:31 Page:357-363
ISSN:0399-077X
Container-title:Médecine et Maladies Infectieuses
language:en
Short-container-title:Médecine et Maladies Infectieuses

Author:

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference35 articles.

1. Infections respiratoires basses de l'adulte : pneumonie communautaire et bronchite aiguë;Med Mal Inf,1999

2. Management of adult community-acquired lower respiratory tract infections;Eur Respir Rev,1998

3. Community-acquired pneumonia in adults: Guidelines for management;Bartlett;Clin Infect Dis,1998

4. Community-acquired pneumonia. Importance of initial non invasive bacteriologic and radiographic investigation;Levy;Chest,1998

5. Nursing home acquired pneumonia. A case control study;Marrie;J Am Geriatr Soc,1990

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of the Pathogens That Are the Cause of Pneumonia by the Battlefield Hypothesis;PLoS ONE;2011-09-01

2. A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia;American Journal of Respiratory and Critical Care Medicine;2007-05-15

3. Antibiotic treatment of community acquired pneumonia varies widely across Germany;Journal of Infection;2007-05

4. Amoxicillin Is Effective against Penicillin-Resistant Streptococcus pneumoniae Strains in a Mouse Pneumonia Model Simulating Human Pharmacokinetics;Antimicrobial Agents and Chemotherapy;2007-01

5. Antibiothérapie des pneumonies aiguës communautaires à Streptococcus pneumoniae : impact clinique de la résistance bactérienne;Médecine et Maladies Infectieuses;2006-11